Ian A Mellis
Overview
Explore the profile of Ian A Mellis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zambrana J, Mellis I, Shotwell A, Maier H, Saborio Y, Barillas C, et al.
medRxiv
. 2025 Feb;
PMID: 39990561
Background: Vaccination prior infection elicit neutralizing antibodies targeting SARS-CoV-2, yet the quantitative relationship between serum antibodies infection risk against viral variants remains uncertain, particularly in underrepresented regions. Methods: We investigated...
2.
Wang Q, Mellis I, Wu M, Bowen A, Gherasim C, Valdez R, et al.
Lancet Infect Dis
. 2025 Feb;
25(3):e133-e134.
PMID: 39919777
No abstract available.
3.
Tarun S, Mellis I, Kilic A, Green D, Tokiwa M, Berry G, et al.
BMC Pediatr
. 2024 Nov;
24(1):776.
PMID: 39604915
Background: Evaluation of suspected neonatal sepsis rarely considers diagnostic workup for vector-borne illnesses, as these are generally infrequent etiologies in the febrile neonate. Babesiosis -- a zoonosis caused by apicomplexan...
4.
Wang Q, Mellis I, Ho J, Bowen A, Kowalski-Dobson T, Valdez R, et al.
Emerg Microbes Infect
. 2024 Sep;
13(1):2402880.
PMID: 39259045
The recently dominant SARS-CoV-2 Omicron JN.1 has evolved into multiple sublineages, with recurrent spike mutations R346T, F456L, and T572I, some of which exhibit growth advantages, such as KP.2 and KP.3....
5.
Wang Q, Mellis I, Guo Y, Gherasim C, Valdez R, Gordon A, et al.
Cell Rep Med
. 2024 Aug;
5(9):101701.
PMID: 39208800
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies are substantially expanded 1 month after a shot of XBB.1.5 monovalent mRNA vaccine (XBB.1.5 MV) booster, but the durability of this response...
6.
Mellis I, Melzer M, Bodkin N, Goyal Y
Genome Biol
. 2024 Aug;
25(1):217.
PMID: 39135102
Background: Cells and tissues have a remarkable ability to adapt to genetic perturbations via a variety of molecular mechanisms. Nonsense-induced transcriptional compensation, a form of transcriptional adaptation, has recently emerged...
7.
Wang Q, Guo Y, Schwanz L, Mellis I, Sun Y, Qu Y, et al.
Emerg Microbes Infect
. 2024 May;
13(1):2359004.
PMID: 38779718
As SARS-CoV-2 continues to spread and mutate, tracking the viral evolutionary trajectory and understanding the functional consequences of its mutations remain crucial. Here, we characterized the antibody evasion, ACE2 receptor...
8.
Wang Q, Guo Y, Bowen A, Mellis I, Valdez R, Gherasim C, et al.
Cell Host Microbe
. 2024 Feb;
32(3):315-321.e3.
PMID: 38377995
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant, but their immunogenicity in humans has yet to be fully evaluated...
9.
Jain N, Goyal Y, Dunagin M, Cote C, Mellis I, Emert B, et al.
Cell Syst
. 2024 Feb;
15(2):109-133.e10.
PMID: 38335955
Pluripotency can be induced in somatic cells by the expression of OCT4, KLF4, SOX2, and MYC. Usually only a rare subset of cells reprogram, and the molecular characteristics of this...
10.
Wang Q, Li Z, Guo Y, Mellis I, Iketani S, Liu M, et al.
iScience
. 2023 Nov;
26(11):108254.
PMID: 38026207
SARS-CoV-2 Omicron BA.2.75 has diversified into multiple subvariants with additional spike mutations and several are expanding in prevalence, particularly CH.1.1 and BN.1. Here, we investigated the viral receptor affinities and...